^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

LB218 - MRE11A expression regulated by UBQLN4 is related to cisplatin-resistance and survival in patients with esophageal squamous cell carcinoma

Published date:
04/09/2021
Excerpt:
...cisplatin-based adjuvant chemotherapy revealed that low MRE11A and high UBLQN4 expression were independent factors to predict shorter overall survival in multivariable analysis (p=0.02, HR=3.74, 95% C.I., 1.19-11.76; p=0.01, HR=5.11, 95% C.I., 1.45-18.03, respectively)....MRE11A and UBQLN4 may serve as predictors for treatment response to cisplatin regimens and prognosis in ESCC patients.